Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2019

Open Access 01-12-2019 | Knee Osteoarthritis | Research

EQ-5D-5L utilities per health states in Spanish population with knee or hip osteoarthritis

Authors: Lidia García-Pérez, Vanesa Ramos-García, Pedro Serrano-Aguilar, José Luis Pais-Brito, María Aciego de Mendoza, Jesús Martín-Fernández, Roberto García-Maroto, Juan Carlos Arenaza, Amaia Bilbao

Published in: Health and Quality of Life Outcomes | Issue 1/2019

Login to get access

Abstract

Background

The objective of this study was to obtain utilities by means of EQ-5D-5L for different health states in patients with knee osteoarthritis (KOA) or hip osteoarthritis (HOA) in Spain, and to compare these values with those used in foreign studies with the aim of discussing their transferability for their use in economic evaluations conducted in Spain.

Methods

Primary study: Observational prospective study of KOA or HOA patients in Spain. Sociodemographic and clinical characteristics were collected to characterize the sample. Utilities were elicited using the EQ-5D-5L questionnaire. ANOVA and bivariable analyses were conducted to identify differences between health states. Literature review: Using the bibliographic databases NSH EED and CEA Registry, we conducted searches of model-based cost utilities analyses of technologies in KOA or HOA patients. Health states and utilities were extracted and compared with values obtained from the Spanish sample.

Results

Three hundred ninety-seven subjects with KOA and 361 subjects with HOA were included, with average utilities of 0.544 and 0.520, respectively. In both samples, differences were found in utilities according to level of pain, stiffness and physical function (WOMAC) and severity of symptoms (Oxford scales), so that the worst the symptoms, the lower the utilities. The utilities after surgery were higher than before surgery. Due to limitations from our study related to sample size and observational design, it was not possible to estimate utilities for approximately half the health states included in the published models because they were directly related to specific technologies. For almost 100% of health states of the selected studies we obtained very different utilities from those reported in the literature.

Conclusions

To our knowledge this is the first article with detailed utilities estimated using the EQ-5D-5L in Spain for KOA and HOA patients. In both populations, utilities are lower for worse health states in terms of level of pain, stiffness and physical function according to WOMAC, and according to the Oxford scales. Most utilities obtained from the Spanish sample are lower than those reported in the international literature. Further studies estimating utilities from local populations are required to avoid the use of foreign sources in economic evaluations.
Appendix
Available only for authorised users
Literature
1.
Pereira D, Peleteiro B, Araújo J, Branco J, Santos RA, Ramos E. The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review. Osteoarthr Cartil. 2011;19:1270–85.PubMed
2.
Xie F, Kovic B, Jin X, He X, Wang M, Silvestre C. Economic and humanistic burden of osteoarthritis: a systematic review of large sample studies. Pharmacoeconomics. 2016;34:1087–100.PubMed
3.
van der Waal JM, Terwee CB, van der Windt DAWM, Bouter LM, Dekker J. The impact of non-traumatic hip and knee disorders on health-related quality of life as measured with the SF-36 or SF-12. A systematic review. Qual Life Res. 2005;14:1141–55.PubMed
4.
Puig-Junoy J, Ruiz ZA. Socio-economic costs of osteoarthritis: a systematic review of cost-of-illness studies. Semin Arthritis Rheum. 2015;44:531–41.PubMed
5.
Loza E, Lopez-Gomez JM, Abasolo L, Maese J, Carmona L, Batlle-Gualda E, et al. Economic burden of knee and hip osteoarthritis in Spain. Arthritis Rheum. 2009;61:158–65.
6.
Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd Edition. New York: Oxford University Press; 2005.
7.
Brazier J, Ara R, Azzabi I, Busschbach J, Chevrou-Séverac H, Crawford B, et al. Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR good practices for outcomes research task force report. Value Health. 2019;22:267–75.PubMed
8.
Vallejo-Torres L, García-Lorenzo B, Castilla I, Valcárcel-Nazco C, García-Pérez L, Linertová R, et al. On the estimation of the cost-effectiveness threshold: why, what, how? Value Health. 2016;19:558–66.
9.
Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Heal Econ. 2018;27:746–61.PubMed
10.
EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.
11.
García-Pérez L, Pinilla-Domínguez P, Aguiar-Ibáñez R, Linertová R, Rivero-Santana A, Abásolo-Alessón I. Revisión sistemática de utilidades o preferencias por los estados de salud obtenidas de población española. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad. Servicio de Evaluación del Servicio Canario de la Salud; 2011.
12.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.PubMedPubMedCentral
13.
Ramos-Goñi JM, Craig BM, Oppe M, Ramallo-Fariña Y, Pinto-Prades JL, Luo N, et al. Handling data quality issues to estimate the Spanish EQ-5D-5L value set using a hybrid interval regression approach. Value Health. 2018;21:596–604.PubMed
14.
Bilbao A, García-Pérez L, Arenaza JC, García I, Ariza-Cardiel G, Trujillo-Martín E, et al. Psychometric properties of the EQ-5D-5L in patients with hip or knee osteoarthritis: reliability, validity and responsiveness. Qual Life Res. 2018;27:2897–908.PubMed
15.
Navarro Espigares JL, Hernández Torres E. Cost-outcome analysis of joint replacement: evidence from a Spanish public hospital. Gac Sanit. 2008;22:337–43.PubMed
16.
Gonzalez Sáenz de Tejada M, Escobar A, Herrera C, García L, Aizpuru F, Sarasqueta C. Patient expectations and health-related quality of life outcomes following total joint replacement. Value Health. 2010;13:447–54.
17.
Allepuz A, Espallargues M, Moharra M, Comas M, Pons JM V, Research group on support instruments - IRYSS network. Prioritisation of patients on waiting lists for hip and knee arthroplasties and cataract surgery: instruments validation. BMC Health Serv Res. 2008;8:76.
18.
Chawla H, Ghomrawi HM, van der List JP, Eggman AA, Zuiderbaan HA, Pearle AD. Establishing age-specific cost-effective annual revision rates for unicompartmental knee arthroplasty: a meta-analysis. J Arthroplasty. 2017;32:326–35.PubMed
19.
Clarke A, Pulikottil-Jacob R, Grove A, Freeman K, Mistry H, Tsertsvadze A, et al. Total hip replacement and surface replacement for the treatment of pain and disability resulting from end-stage arthritis of the hip (review of technology appraisal guidance 2 and 44): systematic review and economic evaluation. Health Technol Assess. 2015;19:1–668, vii–viii.PubMed
20.
Brockbank J, Wolowacz S. Economic evaluations of new oral anticoagulants for the prevention of venous thromboembolism after total hip or knee replacement: a systematic review. Pharmacoeconomics. 2017;35:517–35.PubMed
21.
Pinto D, Robertson MC, Hansen P, Abbott JH. Cost-effectiveness of nonpharmacologic, nonsurgical interventions for hip and/or knee osteoarthritis: Systematic review. Value Health. 2012;15:1–12.PubMed
22.
Hiligsmann M, Cooper C, Arden N, Boers M, Branco JC, Luisa Brandi M, et al. Health economics in the field of osteoarthritis: an Expert’s consensus paper from the European Society for Clinical and Economic Aspects of osteoporosis and osteoarthritis (ESCEO). Semin Arthritis Rheum. 2013;43:303–13.PubMed
23.
Catalá-López F, Ridao M, Alonso-Arroyo A, García-Altés A, Cameron C, González-Bermejo D, et al. The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review. Syst Rev. 2016;5:6.
24.
Gómez-Outes A, Avendaño-Solá C, Terleira-Fernández AI, Vargas-Castrillón E. Pharmacoeconomic evaluation of Dabigatran, rivaroxaban and Apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain. Pharmacoeconomics. 2014;32:919–36.PubMed
25.
Monreal M, Folkerts K, Diamantopoulos A, Imberti D, Brosa M. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. Thromb Haemost. 2013;110:987–94.PubMed
26.
Suárez Fernández C, Gómez Cerezo JF, Gómez Arrayás I, Betegón Nicolás L, de Salas-Cansado M, Rubio-Terrés C. Análisis de coste-efectividad de apixaban frente a enoxaparina en la prevención del tromboembolismo venoso en la artroplastia total de rodilla o cadera. PharmacoEconomics Spanish Res Artic. 2013;10:107–18.
27.
Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health. 2009;12:409–18.PubMed
28.
Heijink R, Reitmeir P, Leidl R. International comparison of experience-based health state values at the population level. Health Qual Life Outcomes. 2017;15:138.
29.
Altman RD. Criteria for classification of clinical osteoarthritis. J Rheumatol Suppl. 1991;27:10–2.
30.
Martín-Fernández J, García-Maroto R, Sánchez-Jiménez FJ, Bau-González A, Valencia-García H, Gutiérrez-Teira B, et al. Validation of the Spanish version of the Oxford knee score and assessment of its utility to characterize quality of life of patients suffering from knee osteoarthritis: a multicentric study. Health Qual Life Outcomes. 2017;15:186.
31.
Martín-Fernández J, Gray-Laymón P, Molina-Siguero A, Martínez-Martín J, García-Maroto R, García-Sánchez I, et al. Cross-cultural adaptation and validation of the Spanish version of the Oxford Hip Score in patients with hip osteoarthritis. BMC Musculoskelet Disord. 2017;18:205.
32.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMed
33.
Dawson J, Fitzpatrick R, Murray D, Carr A. Questionnaire on the perceptions of patients about total knee replacement. J Bone Joint Surg Br. 1998;80:63–9.PubMed
34.
Dawson J, Fitzpatrick R, Carr A, Murray D. Questionnaire on the perceptions of patients about total hip replacement. J Bone Joint Surg Br. 1996;78:185–90.
35.
Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15:1833–40.
36.
37.
Escobar A, Quintana JM, Bilbao A, Azkárate J, Güenaga JI. Validation of the Spanish version of the WOMAC questionnaire for patients with hip or knee osteoarthritis. Western Ontario and McMaster universities osteoarthritis index. Clin Rheumatol. 2002;21:466–71.PubMed
38.
39.
Center for the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry [Internet]. (Boston), Institute for Clinical Research and Health Policy Studies, Tufts Medical Center. Available from: www.​cearegistry.​org. Accessed 8 Aug 2019.
40.
McClure NS, Sayah FA, Xie F, Luo N, Johnson JA. Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores. Value Health. 2017;20:644–50.PubMed
41.
Li CS, Bhandari M. Cost-effectiveness of unicompartmental knee arthroplasty, high tibial osteotomy, and KineSpring® Knee Implant System for unicompartmental osteoarthritis of the knee. J Long Term Eff Med Implants. 2013;23:189–98.PubMed
42.
Li CS, Seeger T, Auhuber TC, Bhandari M. Cost-effectiveness and economic impact of the KineSpring®knee implant system in the treatment for knee osteoarthritis. Knee Surg Sport Traumatol Arthrosc. 2013;21:2629–37.
43.
Losina E, Walensky RP, Kessler CL, et al. Cost-effectiveness of total knee arthroplasty in the United States: patients risk and hospital volume. Arch Intern Med. 2009;169:1113–22.PubMedPubMedCentral
44.
Losina E, Burbine SA, Suter LG, Hunter DJ, Solomon DH, Daigle ME, et al. Pharmacologic regimens for knee osteoarthritis prevention: can they be cost-effective? Osteoarthr Cartil. 2014;22:415–30.PubMedPubMedCentral
45.
Losina E, Daigle ME, Suter LG, Hunter DJ, Solomon DH, Walensky RP, et al. Disease-modifying drugs for knee osteoarthritis: can they be cost-effective? Osteoarthr Cartil. 2013;21:655–67.PubMedPubMedCentral
46.
Mather RC, Hug KT, Orlando LA, Watters TS, Koenig L, Nunley RM, et al. Economic evaluation of access to musculoskeletal care: the case of waiting for total knee arthroplasty. BMC Musculoskelet Disord. 2014;15:22.
47.
Nelson RE, Battistone MJ, Ashworth WD, Barker AM, Grotzke M, Huhtala TA, et al. Cost effectiveness of training rural providers to perform joint injections. Arthritis Care Res. 2014;66:559–66.
48.
Novak EJ, Silverstein MD, Bozic KJ. The cost-effectiveness of computer-assisted navigation in total knee arthroplasty. J Bone Jt Surg - Ser A. 2007;89:2389–97.
49.
Soohoo NF, Sharifi H, Kominski G, Liebeuman JR. Cost-effectiveness analysis of unicompartmental knee arthroplasty as an alternative to total knee arthroplasty for unicompartmental osteoarthritis. J Bone Jt Surg - Ser A. 2006;88:1975–82.
50.
Yen Z-S, Lai M-S, Wang C-T, Chen L-S, Chen S-C, Chen W-J, et al. Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan. J Rheumatol. 2004;31:1797–803.
51.
Bozic KJ, Pui CM, Ludeman MJ, Vail TP, Silverstein MD. Do the potential benefits of metal-on-metal hip resurfacing justify the increased cost and risk of complications? Clin Orthop Relat Res. 2010;468:2301–12.
52.
Cummins JS, Tomek IM, Kantor SR, Furnes O, Engesæter LB, Finlayson SRG. Cost-effectiveness of antibiotic-impregnated bone cement used in primary total hip arthroplasty. J Bone Jt Surg - Ser A. 2009;91:634–41.
53.
Heintzbergen S, Kulin NA, Ijzerman MJ, Steuten LMG, Werle J, Khong H, et al. Cost-utility of metal-on-metal hip resurfacing compared to conventional total hip replacement in young active patients with osteoarthritis. Value Health. 2013;16:942–52.PubMed
54.
McKenzie L, Vale L, Stearns S, McCormack K. Metal on metal hip resurfacing arthroplasty: an economic analysis. Eur J Health Econ. 2003;4:122–9.PubMed
55.
Tso P, Walker K, Mahomed N, Coyte PC, Rampersaud YR. Comparison of lifetime incremental cost: utility ratios of surgery relative to failed medical management for the treatment of hip, knee and spine osteoarthritis modelled using 2-year postsurgical values. Can J Surg. 2012;55:181–90.PubMedCentral
56.
57.
Janssen MF, Bonsel GJ, Luo N. Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics. 2018;36:675–97.PubMedPubMedCentral
58.
Buchholz I, Janssen MF, Kohlmann T, Feng Y-S. A systematic review of studies comparing the measurement properties of the three-level and five-level versions of the EQ-5D. Pharmacoeconomics. 2018;36:645–61.PubMedPubMedCentral
59.
Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, et al. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health. 2016;19:704–19.PubMed
60.
Prodinger B, Taylor P. Improving quality of care through patient-reported outcome measures (PROMs): expert interviews using the NHS PROMs Programme and the Swedish quality registers for knee and hip arthroplasty as examples. BMC health Serv res. BMC Health Serv Res. 2018;18:1–13.
61.
Nwachukwu BU, Bozic KJ, Schairer WW, Bernstein JL, Jevsevar DS, Marx RG, et al. Current status of cost utility analyses in Total joint Arthroplasty: a systematic review. Clin Orthop Relat Res. 2015;473:1815–27.PubMed
Metadata
Title
EQ-5D-5L utilities per health states in Spanish population with knee or hip osteoarthritis
Authors
Lidia García-Pérez
Vanesa Ramos-García
Pedro Serrano-Aguilar
José Luis Pais-Brito
María Aciego de Mendoza
Jesús Martín-Fernández
Roberto García-Maroto
Juan Carlos Arenaza
Amaia Bilbao
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2019
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-019-1230-x

Other articles of this Issue 1/2019

Health and Quality of Life Outcomes 1/2019 Go to the issue

Research

Patient characteristics and valuation changes impact quality of life and satisfaction in total knee arthroplasty – results from a German prospective cohort study

Research

Assessing quality of life in people with HIV in Spain: psychometric testing of the Spanish version of WHOQOL-HIV-BREF

Research

Validation of the Italian version of the abbreviated expanded prostate Cancer index composite (EPIC-26) in men with prostate Cancer

Research

Quality of life among home healthcare patients in Saudi Arabia: household-based survey

Research

Further content validation of the 18-item NCCN/FACT Ovarian Symptom Index and its Disease Related Symptom-Physical (DRS-P) subscale for use in advanced ovarian cancer clinical trials

Research

Fatigue in chronic hepatitis B patients is significant and associates with autonomic dysfunction